We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Trade like a pro: Leverage real-time discussions and market-moving ideas to outperform.
Aeglea BioTherapeutics Inc is a clinical-stage biotechnology company. It designs and develops innovative human enzyme therapeutics for patients with rare genetic diseases and cancer. The company's lead product candidate includes pegzilarginase, a recombinant human Arginase 1 enzyme, which is in an e... Aeglea BioTherapeutics Inc is a clinical-stage biotechnology company. It designs and develops innovative human enzyme therapeutics for patients with rare genetic diseases and cancer. The company's lead product candidate includes pegzilarginase, a recombinant human Arginase 1 enzyme, which is in an early clinical development stage. Show more
Ask ADVFN Intelligence (AI)
Spyre Therapeutics Announces Grants of Inducement Awards PR Newswire WALTHAM, Mass., Dec. 2, 2024 WALTHAM, Mass., Dec. 2, 2024 /PRNewswire/ -- Spyre Therapeutics, Inc. (NASDAQ: SYRE) (the...
Spyre Therapeutics Announces First Participants Dosed in Phase 1 Trials of Novel Half-life Extended Anti-TL1A Antibodies PR Newswire WALTHAM, Mass., Dec. 2, 2024 Spyre is concurrently advancing...
Spyre Therapeutics to Participate in the 7th Annual Evercore ISI HealthCONx Conference PR Newswire WALTHAM, Mass., Nov. 25, 2024 WALTHAM, Mass., Nov. 25, 2024 /PRNewswire/ -- Spyre Therapeutics...
Spyre Therapeutics Announces Pricing of $200 Million Public Offering of Common Stock PR Newswire WALTHAM, Mass., Nov. 18, 2024 WALTHAM, Mass., Nov. 18, 2024 /PRNewswire/ -- Spyre Therapeutics...
Spyre Therapeutics Announces Proposed Public Offering of its Common Stock and Pre-Funded Warrants PR Newswire WALTHAM, Mass., Nov. 18, 2024 WALTHAM, Mass., Nov. 18, 2024 /PRNewswire/ -- Spyre...
| Period | Change | Change % | Open | High | Low | Avg. Daily Vol | VWAP | |
|---|---|---|---|---|---|---|---|---|
| 1 | -1.46 | -5.46407185629 | 26.72 | 27.24 | 23.44 | 469719 | 24.8690417 | CS |
| 4 | -2.47 | -8.90732059142 | 27.73 | 29.09 | 23.44 | 699719 | 26.83512686 | CS |
| 12 | -5.06 | -16.6886543536 | 30.32 | 40.1 | 23.44 | 547456 | 29.89555745 | CS |
| 26 | -6.36 | -20.1138519924 | 31.62 | 40.1 | 22.19 | 614148 | 27.97023061 | CS |
| 52 | 8.43 | 50.0891265597 | 16.83 | 47.97 | 15.37 | 508463 | 29.70837547 | CS |
| 156 | 14.45 | 133.672525439 | 10.81 | 47.97 | 10.42 | 490830 | 29.48276429 | CS |
| 260 | 14.45 | 133.672525439 | 10.81 | 47.97 | 10.42 | 490830 | 29.48276429 | CS |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
